Charles Schwab’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Charles Schwab’s Portfolio OMGA Stock Details OMGA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-65,111	Closed	-$238K	–	3697
2024 Q1	$238K	Hold	65,111	–	–	﹤0.01%	3213
2023 Q4	$196K	Hold	65,111	–	–	﹤0.01%	3278
2023 Q3	$140K	Hold	65,111	–	–	﹤0.01%	3330
2023 Q2	$365K	Buy	+65,111	New	+$509K	﹤0.01%	3180
2022 Q2	–	Sell	-52,799	Closed	-$330K	–	3667
2022 Q1	$330K	Buy	52,799 +33,227	+170%	+$339K	﹤0.01%	3198
2021 Q4	$222K	Hold	19,572	–	–	﹤0.01%	3344
2021 Q3	$369K	Buy	+19,572	New	+$375K	﹤0.01%	3220

Other funds holding OMGA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Charles Schwab's OMGA Position: Q2 2024 in Review

Charles Schwab sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2024, closing a stake of 65,111 shares — an estimated $238K sold.

Charles Schwab first reported a position in OMGA in Q3 2021 and held it in 7 quarters. The position peaked at $369K in Q3 2021. 68 funds tracked by Wall St. Rank hold OMGA as of Q2 2024.

Charles Schwab reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 65,111 Omega Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $238K.
Charles Schwab first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Charles Schwab's Omega Therapeutics, Inc. Common Stock position peaked at $369K in Q3 2021.
68 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.